Misplaced Pages

Reliant Pharmaceuticals

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Reliant Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (June 2015) (Learn how and when to remove this message)
Reliant Pharmaceuticals
IndustryPharmaceuticals
DefunctDecember 2007 (2007-12)
FateAcquired by GlaxoSmithKline
Key peopleJoseph J. Krivulka (co-founder)

Reliant Pharmaceuticals was a company purchased by GlaxoSmithKline in December 2007 for $1.65B. Co-founded by Joseph J. Krivulka.

It was known for six major products, including Lovaza (Omega-3), Axid (H2 blocker), Dynacirc CR (calcium channel blocker), Antara (fenofibrate), InnoPran XL (beta blocker), Lescol XL (Fluvastatin), and Rythmol SR (Class IC anti-arrhythmic).

Reliant Pharmaceuticals, Inc. was a pharmaceutical company that specialized in the development, commercialization and marketing of prescription therapeutic products. Reliant marketed six cardiovascular products in the United States and focused on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliants' sales force consisted of approximately 650 sales and marketing professionals nationwide.

In 2007, Reliant Pharmaceuticals was acquired by GSK for $1.65 billion in cash, after Reliant recorded net sales of $341 million in the nine months leading to September 30, 2007. The Lovaza drug accounted for 60% of the sales of the company for that period.

References

  1. Reliant Redirect – GlaxoSmithKline
  2. "GSK to Acquire Reliant Pharmaceuticals for $1.65B". GEN - Genetic Engineering and Biotechnology News. 2007-11-21. Retrieved 2019-10-21.
  3. Van Arnum, Patricia (2007-11-29). "GlaxoSmithKline to Acquire Reliant Pharmaceuticals for $1.65 Billion". PharmaTech. Retrieved 2019-10-21.
United Kingdom Pharmaceutical and biotechnology industry in the United Kingdom
Companies
Current
Defunct
Government and
regulatory bodies
Industry and
professional bodies
Books and journals
Other


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

Categories:
Reliant Pharmaceuticals Add topic